Sign Out
Among the factors that may increase the risk for NSF are repeated or higher than recommended doses of a GBCA.
For patients receiving haemodialysis, healthcare professionals may consider prompt haemodialysis following GBCA administration in order to enhance the contrast agent's elimination. However, it is unknown if haemodialysis prevents NSF.
Determine the renal function of patients by obtaining a medical history of conducting laboratory tests that measure renal function prior to using GBCA.
The risk, if any, for developing NSF among patients with mild to moderate renal insufficiency or normal renal function is unknown.
Post marketing reports have identified the development of NSF following single and multiple administrations of GBCAs.
